Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects

Abstract

These first clinical data for QGE031, a high-affinity IgG1κ anti-IgE, demonstrate that increased suppression of free IgE compared with omalizumab translated to superior pharmacodynamic effects in atopic subjects, including those with high IgE levels. QGE031 may therefore benefit patients unable to receive, or suboptimally treated with, omalizumab.